TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA said Sept. 28 that it intends to evaluate changes to the framework for reviewing premarket tobacco product applications, including starting rulemaking to replace the current framework. The agency will continue reviewing applications and issuing decisions under existing law while that work proceeds; it has not announced a timetable or proposed new requirements.
The U.S. Food and Drug Administration said on September 28, 2026, that it intends to evaluate changes to the rules governing premarket tobacco product applications, or PMTAs, and may begin rulemaking to replace the current framework. The agency said it will continue reviewing applications and making decisions under existing statutory requirements while it considers changes, leaving manufacturers subject to the current process for now.
The FDA said its review will consider its experience implementing the 2021 PMTA rule and recent judicial developments. It cited a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework. The release did not describe the lawsuit’s specific claims, identify the parties, or say how the case might affect the agency’s review.
The agency also pointed to the widespread development of an illicit and unregulated market and the pace of new product introductions as factors informing its decision. Those are the FDA’s stated reasons for examining the framework; the release did not provide figures about the size of the market or quantify the rate of product introductions.
While the evaluation proceeds, the FDA said it will continue to process PMTA submissions, conduct premarket reviews and issue regulatory decisions. It said those actions will follow requirements set by Congress, including the statutory “appropriate for the protection of public health” standard, commonly abbreviated as APPH. The announcement does not suspend or change that review obligation.
How the Review Could Affect Applicants
A change to the PMTA framework could affect how tobacco product manufacturers prepare applications and how the FDA evaluates them. For companies seeking permission to market new products, clearer requirements and more predictable reviews could influence application planning and product launch decisions. The FDA said it sees a modern framework reflecting current market conditions as important to public health protection, but it has not specified what any revised process would require.
The immediate practical effect is limited: the existing review process continues as the agency considers possible rulemaking. Manufacturers with pending applications still face agency review, and the FDA says it will continue issuing decisions. The announcement therefore signals a potential longer-term regulatory change rather than a current change in application status or marketing authorization.
For the public, the issue concerns how federal oversight handles new tobacco products in a market the FDA describes as including widespread illicit and unregulated sales. The agency has not said whether a replacement framework would change enforcement, application review standards, or the treatment of particular product categories. Any impact on consumers will depend on proposals the FDA may develop and the decisions made through the legal rulemaking process.
The Current PMTA Review Process
The PMTA framework is the FDA’s process for reviewing applications for new tobacco products before they can be legally marketed. Congress established the governing statutory requirements, and the agency’s announcement says its reviews will continue to apply the APPH standard. The FDA’s 2021 rule provides the current regulatory framework it is now reviewing in light of its implementation experience.
The September 28 announcement links three considerations: the agency’s experience applying that rule, court developments that include a challenge in Texas, and market changes involving illicit products and new introductions. It does not say the lawsuit caused the review, nor does it report a court ruling directing the FDA to replace its framework. The agency presents the factors as part of its rationale for evaluating whether changes are warranted.
The FDA described possible new rulemaking as a way to replace the current framework, while also saying future changes would comply with applicable law and include opportunities for public input. That means the announcement marks the start of an evaluation, not publication of a proposed rule. No draft text, specific policy options, or public comment dates were included in the release.
Details of Any New Rules
The FDA has not said when the evaluation will conclude, when it might start rulemaking, or what provisions it could change. The release contains no draft rule, proposed application requirements, implementation dates, or description of how a replacement framework might differ from the 2021 rule.
It is also unclear what role the pending Texas lawsuit will play in the agency’s deliberations. The FDA cited the case as a recent judicial development but did not summarize its claims or say whether it expects a court decision to affect the process. The announcement does not establish that a court has found the current framework unlawful.
The agency provided no data on the illicit market or the pace of new product introductions in this release. It also did not identify changes to the statutory APPH standard; instead, it said current reviews will continue under that standard and statutory requirements. The scope and effect of any eventual regulatory changes remain open.
Rulemaking and Public Input
The next concrete step would be further agency action describing how the evaluation will proceed or issuing a proposed rule. The FDA has not given a schedule for either. If it initiates rulemaking, it says the process will include opportunities for public input and comply with applicable law; the agency has not yet announced a comment period or explained how stakeholders can participate.
In the meantime, the FDA says it will continue to receive and process PMTA submissions, conduct premarket reviews, and issue decisions under existing statutory requirements. Applicants and other interested parties will need to watch for formal FDA notices to learn whether the review produces proposed requirements or a timetable. The current announcement alone does not alter the status of pending applications or authorize products that have not received the required review.
Key Questions
What did the FDA announce?
The FDA said it intends to evaluate changes to the PMTA regulatory framework, including potentially starting rulemaking to replace the current framework.
Are PMTA reviews stopping?
No. The agency said it will continue processing applications, conducting premarket reviews, and issuing decisions under the statutory requirements established by Congress.
Has the FDA proposed new requirements?
No proposed rule or specific new requirements were included in the September 28 announcement. The agency has not provided a timetable for possible rulemaking.
What is the Texas lawsuit about?
The FDA said a federal lawsuit in the U.S. District Court for the Northern District of Texas challenges the current framework. Its release does not detail the lawsuit’s claims or describe a court ruling.
Will the public be able to comment on changes?
The FDA said any future changes will be consistent with applicable law and include opportunities for public input. It has not announced a comment period or other participation details.
Source: primary
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
